{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T16:19:26Z","timestamp":1788365966848,"version":"build-2803163510"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"DOI":"10.1007\/s10067-026-08392-5","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:41:25Z","timestamp":1788363685000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["BAFF\/APRIL-targeted therapy for systemic lupus erythematosus and lupus nephritis: a systematic review and meta-analysis"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1137-0966","authenticated-orcid":false,"given":"Lei","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan-Shan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"8392_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12093198","author":"V Venturelli","year":"2023","unstructured":"Venturelli V, Isenberg DA (2023) Targeted therapy for SLE-what works, what doesn\u2019t, what\u2019s next. J Clin Med. https:\/\/doi.org\/10.3390\/jcm12093198","journal-title":"J Clin Med"},{"issue":"9767","key":"8392_CR2","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0140-6736(10)61354-2","volume":"377","author":"SV Navarra","year":"2011","unstructured":"Navarra SV, Guzm\u00e1n RM, Gallacher AE, Hall S, Levy RA, Jimenez RE et al (2011) Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377(9767):721\u2013731","journal-title":"Lancet"},{"issue":"12","key":"8392_CR3","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1002\/art.30613","volume":"63","author":"R Furie","year":"2011","unstructured":"Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzov\u00e1 D et al (2011) A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 63(12):3918\u201330","journal-title":"Arthritis Rheum"},{"issue":"5","key":"8392_CR4","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1002\/art.40049","volume":"69","author":"W Stohl","year":"2017","unstructured":"Stohl W, Schwarting A, Okada M, Scheinberg M, Doria A, Hammer AE et al (2017) Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study. Arthritis & rheumatology (Hoboken, NJ) 69(5):1016\u20131027","journal-title":"Arthritis & rheumatology (Hoboken, NJ)"},{"issue":"12","key":"8392_CR5","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","volume":"383","author":"R Furie","year":"2020","unstructured":"Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G et al (2020) Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med 383(12):1117\u20131128","journal-title":"N Engl J Med"},{"issue":"15","key":"8392_CR6","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1056\/NEJMoa2414719","volume":"393","author":"RF van Vollenhoven","year":"2025","unstructured":"van Vollenhoven RF, Wang L, Merrill JT, Liu Y, Bao C, Li F et al (2025) A phase 3 trial of telitacicept for systemic lupus erythematosus. N Engl J Med 393(15):1475\u201385","journal-title":"N Engl J Med"},{"issue":"4","key":"8392_CR7","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1136\/ard-2023-224854","volume":"83","author":"D Wu","year":"2024","unstructured":"Wu D, Li J, Xu D, Merrill JT, van Vollenhoven RF, Liu Y et al (2024) Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 83(4):475\u201387","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"8392_CR8","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1002\/art.40360","volume":"70","author":"JT Merrill","year":"2018","unstructured":"Merrill JT, Wallace DJ, Wax S, Kao A, Fraser PA, Chang P et al (2018) Efficacy and safety of atacicept in patients with systemic lupus erythematosus: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled, parallel-arm, phase IIb study. Arthritis & rheumatology (Hoboken, NJ) 70(2):266\u2013276","journal-title":"Arthritis & rheumatology (Hoboken, NJ)"},{"issue":"2","key":"8392_CR9","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1136\/annrheumdis-2015-207653","volume":"75","author":"DA Isenberg","year":"2016","unstructured":"Isenberg DA, Petri M, Kalunian K, Tanaka Y, Urowitz MB, Hoffman RW et al (2016) Efficacy and safety of subcutaneous tabalumab in patients with systemic lupus erythematosus: results from ILLUMINATE-1, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis 75(2):323\u2013331","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"8392_CR10","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1136\/annrheumdis-2015-207654","volume":"75","author":"JT Merrill","year":"2016","unstructured":"Merrill JT, van Vollenhoven RF, Buyon JP, Furie RA, Stohl W, Morgan-Cox M et al (2016) Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis 75(2):332\u2013340","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"8392_CR11","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1136\/annrheumdis-2018-213032","volume":"77","author":"JT Merrill","year":"2018","unstructured":"Merrill JT, Shanahan WR, Scheinberg M, Kalunian KC, Wofsy D, Martin RS (2018) Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 77(6):883\u2013889","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"8392_CR12","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1136\/annrheumdis-2013-205144","volume":"74","author":"RA Furie","year":"2015","unstructured":"Furie RA, Leon G, Thomas M, Petri MA, Chu AD, Hislop C et al (2015) A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. Ann Rheum Dis 74(9):1667\u20131675","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"8392_CR13","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.ard.2025.11.015","volume":"85","author":"N Agmon-Levin","year":"2026","unstructured":"Agmon-Levin N, Ignatenko S, Gordienko A, Cort\u00e9s-Hern\u00e1ndez J, Narongroeknawin P, Romanowska-Pr\u00f3chnicka K et al (2026) B cell depletion and BAFF receptor blockade with ianalumab (VAY736) for the treatment of moderate-to-severe systemic lupus erythematosus: a phase 2 randomised, double-blind, placebo-controlled trial with subsequent open-label treatment. Ann Rheum Dis 85(3):476\u2013488","journal-title":"Ann Rheum Dis"},{"key":"8392_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1445814","volume":"15","author":"X Liu","year":"2024","unstructured":"Liu X, Chen X, Yang C, Li R, Chen X, Li Q (2024) Biologicals for the treatment of lupus nephritis: a Bayesian network meta-regression analysis. Front Immunol 15:1445814","journal-title":"Front Immunol"},{"key":"8392_CR15","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ (Clinical research ed) 372:n71","journal-title":"BMJ (Clinical research ed)"},{"issue":"10","key":"8392_CR16","doi-asserted-by":"publisher","first-page":"ED000142","DOI":"10.1002\/14651858.ED000142","volume":"10","author":"M Cumpston","year":"2019","unstructured":"Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP et al (2019) Updated guidance for trusted systematic reviews: a new edition of the Cochrane handbook for systematic reviews of interventions. Cochrane Database Syst Rev 10(10):ED000142","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"8392_CR17","volume":"18","author":"NR Haddaway","year":"2020","unstructured":"Haddaway NR, Page MJ, Pritchard CC, McGuinness LA (2020) PRISMA2020: an R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and Open Synthesis. Campbell Syst Rev 18(2):e1230","journal-title":"Campbell Syst Rev"},{"key":"8392_CR18","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ (Clinical research ed) 366:l4898","journal-title":"BMJ (Clinical research ed)"},{"issue":"7650","key":"8392_CR19","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P et al (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336(7650):924\u2013926","journal-title":"BMJ"},{"issue":"5","key":"8392_CR20","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1111\/bcp.12860","volume":"81","author":"J Witcher","year":"2016","unstructured":"Witcher J, Fleischmann R, Chindalore VL, Hansen RJ, Hu L, Radtke D et al (2016) Pharmacokinetics and safety of single doses of tabalumab in subjects with rheumatoid arthritis or systemic lupus erythematosus. Br J Clin Pharmacol 81(5):908\u2013917","journal-title":"Br J Clin Pharmacol"},{"key":"8392_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1472292","volume":"15","author":"S Gao","year":"2024","unstructured":"Gao S, Yang C, Huang B, Yang L, Lu L, Yang H et al (2024) Comparative efficacy and safety of different recommended doses of telitacicept in patients with systemic lupus erythematosus in China: a systematic review and meta-analysis. Front Immunol 15:1472292","journal-title":"Front Immunol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08392-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-08392-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08392-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:41:26Z","timestamp":1788363686000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-08392-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":21,"alternative-id":["8392"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-08392-5","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"assertion":[{"value":"29 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"<b>Ethical approval and consent to participate<\/b>","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":3,"name":"Ethics","label":"Disclosures","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}}]}}